The Latest Breaking News from Merck

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

Merck sets sail into new therapeutic waters with the 0 million acquisition of Harpoon Therapeutics, harnessing the power of innovation to navigate treat...

The Dow Jones was unchanged ahead of December payroll data. Apple got a second downgrade for the week while chip-glut shock drove Mobileye down.

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

Looking ahead, 2024 likely will be filled with volatility, uncertainty, complexity, and ambiguity. That’s "VUCA" for you.

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

The Dow Jones hit a record high while the S&P 500, Nasdaq and Russell 2000 set 2023 highs as the Fed signaled multiple rate cuts next year.

The Dow Jones index reached another high but the market weakened in afternoon trading. CAT stock jumped.

Moderna's Merck-partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma patients. Moderna stock soared.

The Dow Jones rallied as Fed Chair Powell and the FOMC served up good news. Tesla stock rose despite a recall while Netflix is near an entry.

It's only November — but if you're like most investors — 2024 is what matters now. And some S&P 500 companies already look primed to put up big numbers.